The 10-years survival rate was estimated to be 96.97% for patients with the low expression of KRT17 and 52.61% for patients with the high expression of KRT17, but there was no correlation with the tumour stage, histological grade or lymph node metastasis (Escobar-Hoyos et al., 2014; Chaloob et al., 2016; Ikeda et al., 2008). The gene discussed is KRT17; the disease is neoplasm.